close Icon

Vaginal Live Biotherapeutics for Women’s Sexual and Reproductive Health

Bacterial vaginosis (BV) is a highly prevalent imbalance in the vaginal microbiome that increases risk of HIV acquisition and adverse birth outcomes. BV remains prevalent partly because existing treatment has limited efficacy. We aim to address this healthcare gap by developing more effective therapeutics to improve treatment outcomes.


To develop live biotherapeutics for BV treatment in different populations.

A key barrier to optimizing women’s sexual and reproductive health is the lack of effective treatment for BV. BV and the adverse outcomes that this condition causes are associated with significant morbidity, mortality and social and economic costs. Developing effective treatment options would improve the quality of life of women who have recurrent BV and has the potential to reduce the rates of infertility, acquisition of sexually transmitted infections including HIV, spontaneous preterm birth, and other adverse birth outcomes. 

Square Lindi.Masson

Contact Person

Contact Doctor Lindi Masson for more information about this project.



  • ACH4
  • South African Medical Research Council

Partners +

  • University of Cape Town, South Africa
  • Desmond Tutu Health Foundation, South Africa
  • Melbourne Sexual Health Centre